Emily M. Geramita

Dr. Emily M. Geramita


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2018 in Journal of Medical Internet Research
Verified
Journal Article
Open access
EGEmily M. Geramita
Emily M. Geramita
BBBea Herbeck Belnap
Bea Herbeck Belnap
KAKaleab Abebe
Kaleab Abebe
SRScott D Rothenberger
Scott D Rothenberger
ARArmando J Rotondi
Armando J Rotondi
BRBruce L Rollman
Bruce L Rollman
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: We recently reported that depressed and anxious primary care patients randomized to a moderated Internet support group (ISG) plus computerized cognitive behavioral therapy (CCBT) did not experience improvements in depression and anxiety over CCBT alone at 6-month follow-up. Objective: The “1% Rule” posits that 1% of participants in online communities generate ~90% of new user-created content. The aims of this study were to apply the 1% Rule to categorize patient engagement with the ISG and identify whether any patient subgroups benefitted from ISG use. Methods: We categorized the 302 patients randomized to the ISG as: superusers (1%, N=3), top contributors (10%, N=30), contributors (36%, N=108), observers (29%, N=87) and those who never logged-in (24%, N=74). We then applied linear mixed models to examine associations between engagement and 6-month changes in health-related quality of life (HRQoL; SF-12 MCS) and depression and anxiety symptoms (PROMIS). Results: At baseline, participants’ mean age was 42.6 years, 81% were female, and mean PHQ-9, GAD-7 and SF-12 MCS scores were 13.4, 12.6 and 31.7, respectively. Of the 76% who logged-in, 62% created ≥1 post (median: 1 [IQR 0,5]); superusers created 40% of posts (median: 246 [IQR 78,306]), top contributors created 38% (median: 11 [IQR 10,18]), and contributors created 22% (median: 3 [IQR 1,5]). Compared to participants who never logged-in, the combined superuser + top contributor subgroup (N=33) reported 6-month improvements in anxiety (PROMIS: -11.6 vs. -7.8; p=.04) and HRQoL (SF-12 MCS: 16.1 vs. 10.1; p=.01) but not in depression. No other subgroup reported significant symptom improvements. Conclusions: Patient engagement with the ISG was more broadly distributed than predicted by the 1% Rule. The 11% of participants with the highest engagement levels reported significant improvements in anxiety and HRQoL. Clinical Trial: ClinicalTrials.gov NCT01482806

6 August 2019 in Journal of Cancer Education
Verified
Journal Article
Closed access
PDF file
EGEmily M. Geramita
Emily M. Geramita
IPIra R. Parker
Ira R. Parker
JBJill W. Brufsky
Jill W. Brufsky
BDBrenda Diergaarde
Brenda Diergaarde
GLG. J. van Londen
G. J. van Londen

14 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
AAAseel Alsouqi
Aseel Alsouqi
EGEmily M. Geramita
Emily M. Geramita
AIAnnie Pearl Im
Annie Pearl Im
Acute Myeloid Leukemia (AML) is an aggressive myeloid malignancy predominantly affecting older adults. Despite the advancements in new therapies for AML, older and medically unfit patients continue to suffer from poor outcomes due to disease-related factors such as the mutational profile and patient-related factors such as comorbidities and performance status. In this review, we discuss a spectrum of therapeutic options for older patients with AML starting with a historical perspective and ending with therapies being investigated in clinical trials. We review the standard of care treatment options including combination venetoclax and hypomethylating agents, in addition to targeted therapies such as FLT3 and IDH inhibitors. Lastly, we shed light on challenges facing the care of older adults and their representation in clinical trials.

25 March 2025 in JCI Insight
Verified
Journal Article
Open access
PDF file
SISawa Ito
Sawa Ito
EGEmily M. Geramita
Emily M. Geramita
KVKedwin Ventura
Kedwin Ventura
BNBiswas Neupane
Biswas Neupane
SBShruti Bhise
Shruti Bhise
WSWarren D. Shlomchik
Warren D. Shlomchik
BACKGROUND: The graft-versus-leukemia (GVL) effect contributes to the efficacy of allogeneic stem cell transplantation (alloSCT). However, relapse, indicative of GVL failure, is the greatest single cause of treatment failure. Based on preclinical data showing that IFN-γ is important to sensitize myeloblasts to alloreactive T cells, we performed a phase I trial of IFN-γ combined with donor leukocyte infusions (DLIs) in myeloblastic malignancies that relapsed after HLA-matched alloSCT. METHODS: Patients with relapsed acute myeloid leukemia or myelodysplastic syndrome after alloSCT were eligible. Patients self-administered IFN-γ for 4 weeks (cohort 1) or 1 week (cohort 2), followed by DLI and concurrent IFN-γ for a total of 12 weeks. Bone marrow samples were analyzed by single-cell RNA sequencing (scRNA-Seq) to assess in vivo responses to IFN-γ by malignant myeloblasts. RESULTS: IFN-γ monotherapy was well tolerated by all participants ( n = 7). Treatment-related toxicities after DLI included grade I–II graft-versus-host disease ( n = 5), immune effector cell–associated neurotoxicity syndrome ( n = 2), and idiopathic pulmonary syndrome ( n = 1), all of which resolved with corticosteroids. Four of 6 DLI recipients achieved minimal residual disease-negative complete remissions and full donor hematopoietic recovery. Median overall survival was 579 days (range, 97–906) in responders. scRNA-Seq validated in vivo activation of the IFN-γ response pathway in hematopoietic stem cell–like or myeloid progenitor cells after IFN-γ in analyzed samples. CONCLUSION: IFN-γ was safe and well tolerated in this phase I study of IFN-γ for relapsed acute myeloid leukemia and myelodysplastic syndrome after alloSCT, with a promising efficacy signal when combined with DLI. Larger studies are needed to formally test the efficacy of this approach. TRIAL REGISTRATION: ClinicalTrials.gov NCT04628338. FUNDING: UPMC Hillman Cancer Center Cancer Immunology and Immunotherapy Program Pilot Award and Cure Within Reach: Drug Repurposing Clinical Trials to Impact Blood Cancers.

1 February 2023 in JCO Oncology Practice
Verified
Journal Article
Closed access
RRRachel E. Rosenblum
Rachel E. Rosenblum
EOEllen Ormond
Ellen Ormond
CSCrystal W. Smith
Crystal W. Smith
ABAndrew L. Bilderback
Andrew L. Bilderback
SDStefanie C. Altieri Dunn
Stefanie C. Altieri Dunn
RARobert M. Arnold
Robert M. Arnold
PURPOSE: Older patients with acute leukemia (AL) have a high symptom burden and poor prognosis. Although integration of palliative care (PC) with oncologic care has been shown to improve quality-of-life and end-of-life care in patients with AL, the malignant hematologists at our tertiary care hospital make limited use of PC services and do so late in the disease course. Using the Plan-Do-Study-Act (PDSA) methodology, we aimed to increase early PC utilization by older patients with newly diagnosed AL. METHODS: We instituted the following standardized criteria to trigger inpatient PC consultation: (1) age 70 years and older and (2) new AL diagnosis within 8 weeks. PC consultations were tracked during sequential PDSA cycles in 2021 and compared with baseline rates in 2019. We also assessed the frequency of subsequent PC encounters in patients who received a triggered inpatient PC consult. RESULTS: The baseline PC consultation rate before our intervention was 55%. This increased to 77% and 80% during PDSA cycles 1 and 2, respectively. The median time from diagnosis to first PC consult decreased from 49 days to 7 days. Among patients who received a triggered PC consult, 43% had no subsequent inpatient or outpatient PC encounter after discharge. CONCLUSION: Although standardized PC consultation criteria led to earlier PC consultation in older patients with AL, it did not result in sustained PC follow-up throughout the disease trajectory. Future PDSA cycles will focus on identifying strategies to maintain the integration of PC with oncologic care over time, particularly in the ambulatory setting.

30 May 2025 in CHEST Pulmonary
Verified
Journal Article
Open access
MHMatthew K. Hensley
Matthew K. Hensley
KSkhaled El Sayed
khaled El Sayed
GHGhady Haidar
Ghady Haidar
XWXiaohong Wang
Xiaohong Wang
PBPanayiotis V. Benos
Panayiotis V. Benos
GKGeorgios D. Kitsios
Georgios D. Kitsios
Diagnosing pulmonary complications (PCs) in hematologic malignancies remains challenging due to insensitive conventional microbiologic testing (CMT) and overlapping clinical manifestations of infectious and noninfectious pulmonary complications. For these reasons, empirical antimicrobials and immunosuppression (eg, corticosteroids) are used for prolonged periods. How does metagenomic sequencing of the lower respiratory tract compare with conventional microbiologic testing among patients with hematologic malignancy? Prospective proof-of-concept cohort study of 30 adult in-patients with hematologic malignancies and PCs who underwent bronchoscopy for suspected lower respiratory tract infection. CMT identified a pathogen via culture- or polymerase chain reaction-based testing in 53% of patients. 16S sequencing demonstrated 66.7% positive and 42.9% negative concordance with CMT, while also identifying additional plausible respiratory pathogens in 59.3% of patients. Nanopore demonstrated 6.7% positive and 87.5% negative concordance with CMT and identified additional plausible respiratory pathogens in 42.3% of patients. Culture-independent sequencing approaches had modest agreement with CMT when considering bacterial PCs and showed poor detection of fungal pathogens. Sequencing frequently identified additional plausible respiratory pathogens, and further validation is needed to determine if such detection represents clinically missed infections or nonpathogenic colonization.